Combined Chemotherapy and Granulocyte Colony-Stimulating Factor (G-CSF) Mobilise Large Numbers of Peripheral Blood Progenitor Cells in Pretreated Patients

References

• To L.B., Roberts M.M., Haylock D.N., Dyson P.G., Branford A.L., et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Trans. 1992; 9: 277–284
   PubMed Web of Science ®Google Scholar
• Bensinger W., Singer J., Appelbaum F., Lilleby K., Longin K., et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158–3163
   PubMed Web of Science ®Google Scholar
• Teshima T., Harada M., Takamatsu Y., Makino K., Tan-Iguchi S., et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Trans. 1992; 10: 215–220
   PubMed Web of Science ®Google Scholar
• Schwartzberg L., Birch R., Blanco R., Wittlin F., Muscato J., et al. Rapid and sustained hematopoietic re-constitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Trans. 1993; 11: 369–374
   PubMed Web of Science ®Google Scholar
• Sheridan W.P., Begley C.G., To L.B., Grigg A., Szer J., et al. Phase II study of autologous Filgrastim (G-CSF)—mobilized peripheral blood progenitor cells to restore hemopoiesis after high dose chemotherapy for lymphoid malignancies. Bone Marrow Trans, in press
   Google Scholar
• Hohaus S., Goldschmidt H., Ehrhardt R., Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp. Hematol. 1993; 21: 508–514
   PubMed Web of Science ®Google Scholar
• Kessinger A., Armitage J.O., Landmark J.D., Smith D.M., Weisenburger D.D. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723–727
   PubMed Web of Science ®Google Scholar
• Chao N.J., Schriber J.R., Grimes K., Long G.D., Ne-Grin R.S., et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035
   PubMed Web of Science ®Google Scholar
• To L.B., Shepperd K.M., Haylock D.N., Dyson P.G., Charles P., et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp. Hematol. 1990; 18: 442–447
   PubMed Web of Science ®Google Scholar
• Nicola N.A., Begley C.G., Metcalf D. Identification of the human analogue of a regulator that induces differentiation in murine leukaemic cells. Nature 1985; 314: 625–628
   PubMed Web of Science ®Google Scholar
• Metcalf D., Begley C.G., Johnson G.R., Nicola N.A., Vadas M.A., et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986; 67: 37–45
   PubMed Web of Science ®Google Scholar
• Sheridan W.P., Begley C.G., Juttner C.A., Szer J., To L.B., Maher D., McGrath K.M., Morstyn G., Fox R.M. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–644
   PubMed Web of Science ®Google Scholar
• Peters W.P., Rosner G., Ross M., Vrendenburgh J., Mei-Senberg B., et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719
   PubMed Web of Science ®Google Scholar
• Haas R., Ho A.D., Bredthauer U., Cayeux S., Egerer G., et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocytemacrophage colony-stimulating factor. Exp. Hematol. 1990; 18: 94–98
   PubMed Web of Science ®Google Scholar
• DeLuca E., Sheridan W.P., Watson D., Szer J., Begley C.G. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br. J. Cancer 1992; 66: 893–899
   PubMed Web of Science ®Google Scholar
• Gianni A.M., Siena S., Bregni M., Tarella C., Stern A.C., et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for auto-transplantation. Lancet 1989; 2: 580–585
   PubMed Web of Science ®Google Scholar
• Pettengell R., Radford J., Scarffe H., Deakin D., Testa N., et al. Peripheral blood progenitor cells (PBPC) for haemopoietic rescue for poor prognosis high grade NHL (abstract). Proc. Am. Assoc. Cancer Res. 1992; 33: 199
   Google Scholar
• Connors J.M., Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin. Hematol. 1988; 25(Suppl. 2)41–46
   PubMed Web of Science ®Google Scholar
• McKelvey E.M., Gottlieb J.A., Wilson H.E., et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Bagley C.M., DeVita V.T., Berard C.W., Canellos G.P. Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine and prednisone. Ann. Intern. Med. 1972; 76: 227–234
   PubMed Web of Science ®Google Scholar
• Miller T.P., Dana B.W., Weick J.K., et al. South-west Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin. Hematol. 1988; 25 (Suppl. 2): 17–22
   Web of Science ®Google Scholar
• Begley C.G., Lopez A.F., Vadas M.A., Metcalf D. The clonal proliferation in vitro of enriched populations of human promyelocytes and myelocytes. Blood 1985; 65: 951–958
   PubMed Web of Science ®Google Scholar
• Srivastava A., Bradstock K.F., Szer J., de Bortoli L., Gottlieb D.J. Busulphan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Trans. 1993; 12: 323–329
   PubMed Web of Science ®Google Scholar
• Sheridan W.P., Boyd A.W., Green M.D., Russell D. M. R., Thomas R. J. S., et al. High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report. Med. J. Aust. 1989; 151: 379–386
   PubMed Web of Science ®Google Scholar
• Kotasek D., Shepherd K.M., Sage R.E., Dale B.M., Norman J.E., et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Trans. 1992; 9: 11–17
   PubMed Web of Science ®Google Scholar
• Janssen W.E., Farmelo M.J., Lee C., Smilee R., Kronish L., et al. The CD34+ cell fraction in bone marrow and blood is not universally predictive of CFU-GM. Exp. Hematol. 1992; 20: 528–530
   PubMed Web of Science ®Google Scholar
• Bender J.G., Lum L., Unverzagt K.L., Van Epps D.E., Williams S.F., et al. Correlation of colony-forming cells, long term culture-initiating cells and CD34+ cells in apheresis products from patients recovering from chemotherapy (abstract). Blood 1992; 80: 517a
   PubMedGoogle Scholar
• Crawford J., Kreisman H., Garewal H., Jones S., Shoemaker D., et al. A pharmacodynamic investigation of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF) schedule variation in patients with small cell lung cancer (SCLC) given CAE chemotherapy (abstract). Proc. Am. Soc. Clin. Oncol. 1992; 11: 299
   Google Scholar